ETC-216 for coronary artery disease.

Abstract

INTRODUCTION:

Increasing attention has focused on the role of high-density lipoprotein function as a target for cardiprotection. Apolipoprotein A-I(Milano) (AIM) involves a single amino-acid mutation of the major wild-type protein carried on high-density lipoprotein (HDL) particles. Early evidence of beneficial activities of AIM has stimulated support in its development as a potential therapy to reduce cardiovascular risk.

AREAS COVERED:

The importance of HDL as a target and early data supporting the beneficial effects of AIM are reviewed. All clinical studies of AIM found in PubMed are reviewed.

EXPERT OPINION:

ETC-216 represents a lipid-deplete form of HDL containing recombinant AIM. While early evidence suggests that administration of ETC-216 promotes rapid regression of coronary atherosclerosis, bringing this compound to clinical practice will require further trials that evaluate its impact on cardiovascular events.

• Authors: Stephen J Nicholls, Kiyoko Uno, Yu Kataoka, Steven E Nissen
• Journal: Expert opinion on biological therapy (Expert Opin Biol Ther) Vol. 11 Issue 3 Pg. 387-94 (Mar 2011) ISSN: 1744-7682 [Electronic] England
• PMID: 21271950 (Publication Type: Journal Article, Review)

Chemical References

• Anticholesteremic Agents
• Apolipoprotein A-I
• Cholesterol, HDL
• ETC216
• Phosphatidylcholines

Topics

• Animals
• Anticholesteremic Agents (therapeutic use)
• Apolipoprotein A-I (therapeutic use)
• Cholesterol, HDL (blood)
• Coronary Artery Disease (blood, drug therapy)
• Evidence-Based Medicine
• Humans
• Phosphatidylcholines (therapeutic use)
• Treatment Outcome